(PharmaNewsWire.Com, August 26, 2017 ) Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Pipeline Review, H2 2017”. Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Insulin-like growth factor 2 (IGF-2) is a protein hormone. IGF-2 is influenced by placental lactogen and plays a role in fetal development.
It undergoes glucose-mediated co-secretion with insulin and acts as physiological amplifier of glucose-mediated insulin secretion. It exhibits osteogenic properties by increasing osteoblast mitogenic activity through phosphoactivation of MAPK1 and MAPK3.
Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) pipeline Target constitutes close to 9 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 3 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System and Musculoskeletal Disorders which include indications Metastatic Breast Cancer, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Breast Cancer, Hormone Sensitive Breast Cancer, Huntington Disease, Ischemic Cerebral Stroke, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Muscular Dystrophy, Neuroblastoma, Non-Small Cell Lung Cancer, Parkinson's Disease and Solid Tumor.
The latest report Insulin Like Growth Factor II - Pipeline Review, H2 2017, outlays comprehensive information on the Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - The report reviews Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics and enlists all their major and minor projects - The report assesses Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Overview 6 Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Therapeutics Development 7 Products under Development by Stage of Development 7 Products under Development by Therapy Area 8 Products under Development by Indication 9 Products under Development by Companies 10 Products under Development by Universities/Institutes 12 Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Therapeutics Assessment 14 Assessment by Mechanism of Action 14 Assessment by Route of Administration 16 Assessment by Molecule Type 18 Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Companies Involved in Therapeutics Development 20 Boehringer Ingelheim GmbH 20 Genervon Biopharmaceuticals LLC 20 MedImmune LLC 21 Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Drug Profiles 22 dusigitumab - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 GM-6 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 M-610.27 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 M-630 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 M-7085 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Recombinant Protein to Inhibit IGF-1 and IGF-2 for Breast Cancer - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
